> Grünenthal Portugal

Innovating To Improve The Lives Of People With Chronic Pain

Grünenthal, SA is a subsidiary of Grünenthal GmbH, with a presence in Portugal since 1990, which is dedicated to the marketing of pharmaceutical products and a leader in medicines for the treatment of moderate to severe pain. Our mission is to improve the lives of people living with chronic pain.

Innovating to improve patients’ lives

As a global leader in research and development in the field of pain, we keenly explore new treatment options with the potential to improve the lives of patients around the world. Every day, Grünenthal’s researchers use their knowledge to address important medical needs that still have no solution and to rethink the future of pain management. We are an ambitious and dynamic company with a product line geared towards innovation, which allows us to grow from our pain-centred skills. Our Research and Development (R&D) component allows us to explore innovative solutions and cutting-edge technology in the area of pain.

Worldwide presence, local leadership

Headquartered in Aachen, Germany, Grünenthal is present in about 29 countries, with branches in Europe, Latin America and the United States. Our products are sold in more than 100 countries and we have approximately 4,500 employees worldwide. In Portugal, Grünenthal has an experienced team, made up of 46 employees. In 2020, it was recognised as one of the Best Companies to Work for in Portugal and received the Great Place to Work® certification, which distinguishes the quality of the work environment provided to employees by the company. These distinctions are a reflection of our team’s passion, respect and commitment to the mission of improving the quality of life of people living with chronic pain.

Knowing the prevalence of chronic pain in Portugal

Grünenthal Portugal promoted a pioneering study—“Chronic Pain Care – Prevalence and Characterisation of Chronic Pain in Primary Health Care”— carried out in primary care units of the North, Centre, Lisbon and Tagus Valley and Alentejo Regional Health Administrations (RHA). This study estimated a prevalence of chronic pain in primary care units patients of 34% of individuals in Primary Health Care (PHC).1

Every two years, Grünenthal organises one of the largest meetings on the subject of Pain in Portugal, the Future Forum, an initiative that aims to debate the state of the art of pain in Portugal and which brings together more than 200 health professionals and experts.

Another benchmark project carried out by Grünenthal is the digital platform dor.com.pt, a website with differentiated information for patients and health professionals and relevant content about pain and its different types, practical advice and tools to support diagnosis and pain control.

1-Antunes F., et al., Prevalence and characteristics of chronic pain in patients attending primary care units in continental Portugal: An observational study. Poster presented at EFIC’s congress 2019

Grünenthal

Submit your Innovation Story

Join and network with a global community of innovators  by sharing your success story with the world.